About:Energy, a battery technology company, has recently completed a successful seed funding round of £1.5 million. The financing will be allocated towards the rapid commercialisation and development of their software platform, The Voltt, which significantly reduces the cost to design new battery products through virtual prototyping. Shortening battery design timelines will contribute significantly to industry decarbonisation. The funds will also be used to scale their battery lab in London and expand the team. The round also included participation from Theodo CTO Fabrice Bernhard, Coltrane Asset Management Partners' Laura Webster, Mandeep Manku, Nick Banner, among many others.
The spin-out from University College London sells its full portfolio of AI solutions in the successful exit of a commercialised research project and Olympus announce plans to establish Digital Excellence Centres
Hypervision Surgical, a London-based venture building an advanced surgical imaging and data analytics platform, announced the successful completion of an oversubscribed seed funding round, raising £6.5 million. By harnessing AI and clinical edge computing, the King’s College London spin-out aims to revolutionise surgical outcomes and alleviate the global burden of surgical complications across diverse surgical specialties.
OXFORD, England, April 17, 2023 /PRNewswire/ — Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, today announced it has secured a further £13 million (US$16.3 million) to conclude its Series A financing round. Caristo will use the capital to advance its CaRi-Heart® technology, an AI-assisted diagnostics and risk prediction tool, into standards of cardiac care in major global markets.
One of Britain’s biggest banks is getting behind a startup making car ownership less of a hassle, particularly in city centers, where failing to keep up with all manner of taxes and tolls can lead to big fines.
LLoyds Banking Group Plc has put £4 million ($5 million) into Caura, a four-year-old company already backed by Jaguar Land Rover’s venture arm, in its third fintech investment since last year.
Oxford, UK, 19 October 2022 – Nucleome Therapeutics Limited, (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, today announces it has closed an oversubscribed £37.5 million Series A financing round. The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.